Target detection has always been a hotspot in image processing/computer vision research, and small-target detection is a frequently encountered problem in the field of target detection. With the continuous innovation of target detection technology, people always hope that the detection of small targets can reach the real-time accuracy of large-target detection. In this paper, a small-target detection model based on dual-core convolutional neural networks (CNN) is proposed, which is mainly used for the intelligent detection of books in the production line of printed books. The model is mainly composed of two modules, including a region prediction module and suspicious target search module. The region prediction module uses a CNN to predict suspicious region blocks in a large context. The suspicious target search module uses a different CNN from the above to find tiny targets in the predicted region blocks. Comparative testing of four small book target samples using this model shows that this model has better book small-target detection accuracy compared to other models.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10748197 | PMC |
http://dx.doi.org/10.3390/s23249880 | DOI Listing |
Alzheimers Dement
December 2024
Washington University School of Medicine, St. Louis, MO, USA.
Background: Alzheimer's disease neuropathology involves the deposition in brain of aggregates enriched with microtubule-binding-region (MTBR) of tau adopting an abnormal conformation between residues 306-378 in the core of aggregates. Anti-tau drugs targeting around this domain have the potential to interfere with the cell-to-cell propagation of pathological tau. Bepranemab is a humanized monoclonal Ig4 antibody binding to tau residues 235-250.
View Article and Find Full Text PDFBackground: To improve clinical translatability of non-clinical in-vivo Alzheimer's disease (AD) models, a humanized APP knock-in mouse model (APP) was recently created (Xia, D. et al., 2022).
View Article and Find Full Text PDFBackground: Alzheimer's disease (AD) clinical trials led to the recent successes with monoclonal antibodies targeting amyloid, which opens up many new directions for research into treatment for AD in the future. Gaining greater understanding from these successes and failures will help researchers to focus their efforts on avenues that have the highest potential benefit.
Method: We performed a meta-analysis of over a hundred studies of 70+ AD treatments.
Alzheimers Dement
December 2024
Stanford University School of Medicine, Stanford, CA, USA.
Recent advances in biomarkers, enabling the in vivo detection of pathological aggregates of alpha-synuclein (asyn), allow a shift from a clinical to a biological definition of Parkinson's disease (PD) and dementia with Lewy bodies (DLB). The newly proposed "Neuronal alpha-Synuclein Disease (NSD)" is defined by the presence of pathologic neuronal (n-asyn) species detected in vivo (S), irrespective of any specific clinical syndrome. Additional biological anchors include dopaminergic neuronal dysfunction (D).
View Article and Find Full Text PDFBackground: Alzheimer's disease (AD) presents unique challenges in clinical trials involving small molecules. Multifaceted issues plague such trials, emphasizing susceptibility to fraud from clinical sites and "professional patients". The relative ease of simulating Alzheimer's diagnosis, coupled with inadequate oversight by Contract Research Organizations (CROs), creates fertile ground for deceptive practices.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!